CAS Insight

molecules of the month


oral sel. estrogen receptor degrader (SERD)

400 mg QD, in Ph. II for ER+/HER2- BC

from MTS of ER binders, opt. for degrd./antag.

Mol. Cancer Ther., Dec. 11, 2020

Sanofi, Vitry-sur-Seine, FR / Cambridge MA

Chemical structure of molecule SAR439859
1 min read

Sanofi oral selective estrogen receptor (ER) degrader (SERD)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: